Here are five points:
1. The submission regards its DenerveX System, which is designed to treat facet joint pain.
2. In a press release, Medovex’s Senuior Vice President of Regulatory and Clinical Affairs Jill Schweiger said, “Converting the IDE submission to a pre-submission beneficially allows us to engage in a more interactive and collaborative review of the planned clinical investigation.”
3. Medovex believes working with the FDA earlier in the process of the planned clinical evaluation will boost the study’s efficacy and outcomes.
4. The DenerveX System has the CE Mark.
5. Medovex is collaborating with physicians in the U.K. and Germany to gather data on outcomes with the DenerveX System.
More articles on devices:
How to improve surgeon satisfaction in the operating room? Mizuho OSI executive explains
Life Spine, Globus Medical & more: 3 device company notes
Medical device tax reinstatement has device makers panicking — 7 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
